Cosmetic Dermatology

Therapies for Actinic Keratosis With a Focus on Cosmetic Outcomes

Author and Disclosure Information

 

References

Overall, PDT is an excellent therapeutic option that is able to provide efficacious clearance of AKs as well as superior cosmetic outcomes. Common AEs of PDT include burning, itching, and stinging during therapy, but pain intensity decreases dramatically upon termination of illumination, with cessation of most symptoms by 12 hours posttherapy.73 Permanent pigmentation changes have been reported to occasionally occur following PDT therapy.81

Conclusion

When determining which therapy to use in a patient, clinicians must take into account a variety of factors such as patient preference, cost of treatment, availability, tolerance for AEs, and the need for field therapy. Although all therapies discussed within this article are effective and reasonable treatment choices, patients who are particularly concerned about cosmetic outcomes would most likely benefit from either IMQ or PDT, as the data for cosmetic outcomes with these therapies are the strongest. Combination or sequential treatments may be required in some cases and all patients should be monitored for lesion recurrence regardless of treatment choice. A summary of the therapies and key studies discussed here is available in the PDF.

Pages

Recommended Reading

Fractional laser resurfacing plus ALA-PDT upped AK clearance
MDedge Dermatology
Imaging guides BCC laser ablation
MDedge Dermatology
VIDEO: Larger lentigo maligna lesions increase risk
MDedge Dermatology
VIDEO: Updating the immune response to nonmelanoma skin cancer
MDedge Dermatology
Nicotinamide cuts rate of nonmelanoma skin cancer in those at high risk
MDedge Dermatology
Simulated daylight PDT advantageous for AKs
MDedge Dermatology
Ingenol mebutate for AKs gets thumbs-up from patients
MDedge Dermatology
Ingenol mebutate helped clear actinic keratoses
MDedge Dermatology
Daylight photodynamic therapy best for disseminated actinic keratoses
MDedge Dermatology
Picato adverse events prompt FDA warning
MDedge Dermatology

Related Articles